Study identifies mutations outside of traditional vaccine targets as barrier to vaccine development – Johns Hopkins Medicine
Unlike its viral cousins hepatitis A and B, hepatitis C virus (HCV) has eluded the development of a vaccine and infected more than 170 million people worldwide. Now, researchers at Johns Hopkins Medicine report that a novel laboratory tool that lets them find virus mutations faster and more efficiently than ever before has ident
The study, which is the first phase-1 vaccine study in HIV infected people in Ireland, is also the first of a planned number of early intervention studies to be carried out in the Wellcome Trust-HRB Clinical Research Facility, a joint enterprise between Trinity College Dublin and St James's Hospital.The research team are evaluating the safety and the ability of a new vaccine to produce an immune response against Hepatitis C. Previous healthy volunteer stud
Wonderful cures for hepatitis C are on the horizon, but no disease has been eradicated from the world by a cure alone; to really stamp out a disease, we also need widespread use of a preventive vaccine, such as for polio or smallpox. A vaccine for hepatitis C is being developed by GlaxoSmithKline and researchers at Oxford University, based on the same technology being used to develop an Ebola vaccine. For more information, see
"GSK hepatitis C shot shows
